Raymond James Trust’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $3.48M | Sell |
22,357
-5,619
| -20% | -$907K | 0.08% | 221 |
|
|
2024
Q2 | $4.36M | Sell |
27,976
-1,765
| -6% | -$266K | 0.1% | 181 |
|
|
2024
Q1 | $4.03M | Buy |
29,741
+1,219
| +4% | +$161K | 0.1% | 194 |
|
|
2023
Q4 | $3.84M | Sell |
28,522
-2,948
| -9% | -$383K | 0.1% | 189 |
|
|
2023
Q3 | $4.26M | Buy |
31,470
+1,778
| +6% | +$243K | 0.13% | 160 |
|
|
2023
Q2 | $4.25M | Sell |
29,692
-4,058
| -12% | -$597K | 0.12% | 161 |
|
|
2023
Q1 | $4.69M | Sell |
33,750
-696
| -2% | -$93.6K | 0.15% | 142 |
|
|
2022
Q4 | $4.67M | Sell |
34,446
-1,146
| -3% | -$144K | 0.16% | 134 |
|
|
2022
Q3 | $3.9M | Sell |
35,592
-143
| -0.4% | -$18.1K | 0.15% | 139 |
|
|
2022
Q2 | $4.72M | Sell |
35,735
-932
| -3% | -$122K | 0.17% | 129 |
|
|
2022
Q1 | $4.87M | Buy |
36,667
+2,419
| +7% | +$290K | 0.15% | 136 |
|
|
2021
Q4 | $3.99M | Buy |
34,248
+2,337
| +7% | +$275K | 0.12% | 162 |
|
|
2021
Q3 | $3.83M | Buy |
31,911
+15,057
| +89% | +$1.75M | 0.13% | 151 |
|
|
2021
Q2 | $2.02M | Buy |
16,854
+886
| +6% | +$97.2K | 0.07% | 252 |
|
|
2021
Q1 | $1.59M | Buy |
15,968
+3,594
| +29% | +$361K | 0.06% | 273 |
|
|
2020
Q4 | $1.24M | Sell |
12,374
-2,242
| -15% | -$237K | 0.05% | 306 |
|
|
2020
Q3 | $1.6M | Buy |
14,616
+1,302
| +10% | +$145K | 0.07% | 234 |
|
|
2020
Q2 | $1.41M | Sell |
13,314
-92
| -0.7% | -$9.5K | 0.07% | 238 |
|
|
2020
Q1 | $1.2M | Buy |
13,406
+403
| +3% | +$37.9K | 0.07% | 238 |
|
|
2019
Q4 | $1.3M | Sell |
13,003
-1,548
| -11% | -$146K | 0.06% | 258 |
|
|
2019
Q3 | $1.3M | Sell |
14,551
-896
| -6% | -$77.7K | 0.07% | 251 |
|
|
2019
Q2 | $1.27M | Sell |
15,447
-636
| -4% | -$49.9K | 0.07% | 245 |
|
|
2019
Q1 | $1.3M | Sell |
16,083
-8,331
| -34% | -$657K | 0.08% | 235 |
|
|
2018
Q4 | $1.85M | Sell |
24,414
-2,927
| -11% | -$229K | 0.12% | 175 |
|
|
2018
Q3 | $2.16M | Sell |
27,341
-5,082
| -16% | -$384K | 0.12% | 177 |
|
|
2018
Q2 | $2.28M | Sell |
32,423
-1,611
| -5% | -$116K | 0.14% | 156 |
|
|
2018
Q1 | $2.38M | Buy |
34,034
+1,840
| +6% | +$127K | 0.16% | 140 |
|
|
2017
Q4 | $2.23M | Buy |
32,194
+2,206
| +7% | +$149K | 0.15% | 150 |
|
|
2017
Q3 | $2.03M | Buy |
29,988
+2,530
| +9% | +$160K | 0.15% | 155 |
|
|
2017
Q2 | $1.87M | Buy |
27,458
+741
| +3% | +$48.4K | 0.14% | 157 |
|
|
2017
Q1 | $1.66M | Buy |
26,717
+7,108
| +36% | +$414K | 0.13% | 169 |
|
|
2016
Q4 | $1.07M | Sell |
19,609
-1,867
| -9% | -$106K | 0.09% | 224 |
|
|
2016
Q3 | $1.41M | Buy |
21,476
+9,604
| +81% | +$628K | 0.12% | 171 |
|
|
2016
Q2 | $717K | Sell |
11,872
-98
| -0.8% | -$5.69K | 0.06% | 270 |
|
|
2016
Q1 | $674K | Sell |
11,970
-3,501
| -23% | -$210K | 0.06% | 274 |
|
|
2015
Q4 | $1.05M | Buy |
15,471
+4,690
| +44% | +$307K | 0.1% | 200 |
|
|
2015
Q3 | $686K | Buy |
10,781
+3,530
| +49% | +$232K | 0.08% | 243 |
|
|
2015
Q2 | $462K | Sell |
7,251
-234
| -3% | -$16K | 0.05% | 335 |
|
|
2015
Q1 | $513K | Buy |
7,485
+1,851
| +33% | +$129K | 0.05% | 314 |
|
|
2014
Q4 | $396K | Buy |
5,634
+278
| +5% | +$19.9K | 0.04% | 378 |
|
|
2014
Q3 | $382K | Buy |
5,356
+192
| +4% | +$14.1K | 0.04% | 366 |
|
|
2014
Q2 | $384K | Sell |
5,164
-15,484
| -75% | -$1.12M | 0.04% | 365 |
|
|
2014
Q1 | $1.34M | Buy |
20,648
+277
| +1% | +$17.9K | 0.16% | 130 |
|
|
2013
Q4 | $1.21M | Buy |
20,371
+448
| +2% | +$24.3K | 0.16% | 139 |
|
|
2013
Q3 | $1.03M | Buy |
19,923
+2,796
| +16% | +$140K | 0.16% | 144 |
|
|
2013
Q2 | $810K | Buy |
+17,127
| New | +$872K | 0.13% | 161 |
|
Other funds holding AZN
Raymond James Trust's AZN Position: Q3 2024 in Review
Raymond James Trust reduced its AstraZeneca (AZN) stake by 20% in Q3 2024, selling an estimated $907K and leaving 22,357 shares worth $3.48M. The position accounts for 0.08% of the portfolio, ranked #221.
Raymond James Trust first reported a position in AZN in Q2 2013 and has held it in 46 quarters since. The position peaked at $4.87M in Q1 2022. 1,229 funds tracked by Wall St. Rank hold AZN as of Q3 2024.
- Raymond James Trust held 22,357 shares of AstraZeneca worth $3.48M as of Q3 2024.
- Raymond James Trust sold 5,619 AstraZeneca shares in Q3 2024, an estimated $907K.
- AstraZeneca made up 0.08% of Raymond James Trust's portfolio in Q3 2024, its #221 holding.
- Raymond James Trust first reported a position in AstraZeneca in Q2 2013 and has held it in 46 quarters since.
- Raymond James Trust's AstraZeneca position peaked at $4.87M in Q1 2022.
- 1,229 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2024.
Based on Raymond James Trust's 13F filing for Q3 2024, filed 12 Nov 2024.